The Brazilian pharmaceutical market ranks first in Latin America, with a total revenue exceeding US $26 billion per year, and demand will continue to rise by about 15% annually. Better income distribution and social programs are granting more and more of Brazil’s 191 million people access to health services and medicines.
The Brazilian pharmaceutical industry has increased its production by 50% within the last five years, but it still strongly relies on foreign raw materials and imports worth more than US $2 billion per year. Brazil also has a very dynamic bio-equivalent generic sector, which accounts for 20% of the total market; in the last two years, foreign producers have started actively and successfully penetrating this area.
Currently, Brazil has five leading pharmacy chains that offer strong competition: Drogaria São Paolo, Drogarias Pacheco and Drogasil, which includes Droga Raia and Raia Drogasil.